Biomarkers for personalised treatment in psychiatric diseases

Bibliography

• Sullivan PF, Daly MJ, O'Donovan M. Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat Rev Genet 2012;13(8):537-51
   PubMed Web of Science ®Google Scholar
• Thomas D. Gene–environment-wide association studies: emerging approaches. Nat Rev Genet 2010;11(4):259-72
   PubMed Web of Science ®Google Scholar
• Smoller JW, Craddock N, Kendler K, et al. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013;381(9875):1371-9
   PubMed Web of Science ®Google Scholar
• Lazary J, Lazary A, Gonda X, et al. New evidence for the association of the serotonin transporter gene (SLC6A4) haplotypes, threatening life events, and depressive phenotype. Biol Psychiatry 2008;64(6):498-504
   PubMed Web of Science ®Google Scholar
• Karg K, Burmeister M, Shedden K, Sen S. The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch Gen Psychiatry 2011;68(5):444-54
   PubMed Web of Science ®Google Scholar
• Murphy DL, Uhl GR, Holmes A, et al. Experimental gene interaction studies with SERT mutant mice as models for human polygenic and epistatic traits and disorders. Genes Brain Behav 2003;2(6):350-64
   PubMed Web of Science ®Google Scholar
• Pezawas L, Meyer-Lindenberg A, Goldman AL, et al. Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression. Mol Psychiatry 2008;13(7):709-16
   PubMed Web of Science ®Google Scholar
• Lazary J, Lazary A, Gonda X, et al. Promoter variants of the cannabinoid receptor 1 gene (CNR1) in interaction with 5-HTTLPR affect the anxious phenotype. American journal of medical genetics Part B. Neuropsychiat Genet 2009;150B(8):1118-27
   PubMed Web of Science ®Google Scholar
• Lazary J, Juhasz G, Hunyady L, Bagdy G. Personalized medicine can pave the way for the safe use of CB(1) receptor antagonists. Trends Pharmacol Sci 2011;32(5):270-80
   PubMed Web of Science ®Google Scholar
• Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69(3):89-95
   PubMed Web of Science ®Google Scholar
• Lenzenweger MF. Endophenotype, intermediate phenotype, biomarker: definitions, concept comparisons, clarifications. Depress Anxiety 2013;30(3):185-9
   PubMed Web of Science ®Google Scholar
• Meyer-Lindenberg A, Weinberger DR. Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat Rev Neurosci 2006;7(10):818-27
   PubMed Web of Science ®Google Scholar
• Walters JT, Owen MJ. Endophenotypes in psychiatric genetics. Mol Psychiatry 2007;12(10):886-90
   PubMed Web of Science ®Google Scholar
• Juhasz G, Dunham JS, McKie S, et al. The CREB1-BDNF-NTRK2 pathway in depression: multiple gene-cognition-environment interactions. Biol Psychiatry 2011;69(8):762-71
   PubMed Web of Science ®Google Scholar
• Bagdy G, Juhasz G, Gonda X. A new clinical evidence-based gene-environment interaction model of depression. Neuropsychopharmacol Hung 2012;14(4):213-20
   PubMedGoogle Scholar
• Sun H, Kennedy PJ, Nestler EJ. Epigenetics of the depressed brain: role of histone acetylation and methylation. Neuropsychopharmacology 2013;38(1):124-37
   PubMed Web of Science ®Google Scholar
• Arnone D, McKie S, Elliott R, et al. Increased amygdala responses to sad but not fearful faces in major depression: relation to mood state and pharmacological treatment. Am J Psychiatry 2012;169(8):841-50
   PubMed Web of Science ®Google Scholar
• Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet 2011;12(1):56-68
   PubMed Web of Science ®Google Scholar
• Cline BH, Steinbusch HW, Malin D, et al. The neuronal insulin sensitizer dicholine succinate reduces stress-induced depressive traits and memory deficit: possible role of insulin-like growth factor 2. BMC Neurosci 2012;13:110
   PubMed Web of Science ®Google Scholar
• Uher R, Tansey KE, Malki K, Perlis RH. Biomarkers predicting treatment outcome in depression: what is clinically significant? Pharmacogenomics 2012;13(2):233-40
   PubMed Web of Science ®Google Scholar
• Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9(4):363-72
   PubMed Web of Science ®Google Scholar
• Uher R. The role of genetic variation in the causation of mental illness: an evolution-informed framework. Mol Psychiatry 2009;14(12):1072-82
   PubMed Web of Science ®Google Scholar